

ACURA PHARMACEUTICALS, INC  
Form 8-K  
March 23, 2015

UNITED STATES

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D. C. 20549**

---

FORM 8-K

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act Of 1934**

**March 23, 2015**

Date of Report (Date of earliest event reported)

---

**ACURA PHARMACEUTICALS, INC.**

(Exact Name of Registrant as Specified in Charter)

---

|   |                |   |
|---|----------------|---|
| <b>State of New York</b>  | <b>1-10113</b> | <b>11-0853640</b>                       |
| (State of Other Jurisdiction (Commission File Number) of Incorporation) |                | (I.R.S. Employer Identification Number) |

616 N. North Court, Suite 120

Edgar Filing: ACURA PHARMACEUTICALS, INC - Form 8-K

Palatine, Illinois 60067

(Address of principal executive offices) (Zip Code)

**(847) 705-7709**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-J(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-L(c))

**Item 8.01 Other Events**

On March 23, 2015 we issued a press release announcing preliminary topline results from a pilot clinical study which demonstrated bioequivalence of one formulation of NEXAFED® (pseudoephedrine HCl) extended-release tablets to Sudafed® 12-Hour Tablets. The press release is attached hereto and filed as Exhibit 99.1.

**Item 9.01 Financial Statements and Exhibits**

**Exhibit Number Description**

|      |                                    |
|------|------------------------------------|
| 99.1 | Press Release dated March 23, 2015 |
|------|------------------------------------|

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**ACURA PHARMACEUTICALS, INC.**

By: /s/ Peter A. Clemens  
Peter A. Clemens  
Senior Vice President & Chief Financial Officer

Date: March 23, 2015

**Exhibit Index**

**Exhibit Number Description**

|      |                                    |
|------|------------------------------------|
| 99.1 | Press Release dated March 23, 2015 |
|------|------------------------------------|